Click on headlines below to download research

Termination of coverage
Vernalis | 21/06/2018

Edison Investment Research is terminating coverage on Vernalis (VER). Please note you should no longer rely on any previous research or estimates for this…

Tuzistra XR downgrade prompts strategic rethink
Vernalis | 28/02/2018

Vernalis has provided a trading and operational update to its guidance for Tuzistra XR prescriptions for financial year-end 2018. Despite dynamic management…

Operational initiatives in place, execution is key
Vernalis | 22/11/2017

Tuzistra XR prescriptions (Rx) grew threefold to ~35k in FY16/17 (2nd year on the market) vs ~12k in FY15/16. Investment into addressing the barriers to…